WCLC 2022 | Key takeaways from WCLC 2022
Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, shares his highlights from the IASLC 2022 World Conference on Lung Cancer congress, including new data on combining a SHIP inhibitor with sotorasib safety and effectively in previously treated patients. Additionally, combining sotorasib with either pembrolizumab or atezolizumab previously induced significant liver adverse events in patients previously treated with immunotherapy, however, new investigations have found how these problems can be mitigated. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
Transcript (edited for clarity)
So the highlights of this meeting here in Vienna are many. One of the highlights for me, I think has been the molecular oncology oral presentation, looking at KRAS mutant non-small cell lung cancer. And, here we heard new data on combination of the revolution medicines SHIP inhibitor together with sotorasib demonstrating that it can be combined relatively safely with no apparent maximum tolerated dose and very, on the face of it, controllable low-grade adverse events with some evidence of efficacy, even in patients that have been previously treated...
So the highlights of this meeting here in Vienna are many. One of the highlights for me, I think has been the molecular oncology oral presentation, looking at KRAS mutant non-small cell lung cancer. And, here we heard new data on combination of the revolution medicines SHIP inhibitor together with sotorasib demonstrating that it can be combined relatively safely with no apparent maximum tolerated dose and very, on the face of it, controllable low-grade adverse events with some evidence of efficacy, even in patients that have been previously treated. And I think we need to keep an eye on that space.
But importantly, we had data on combining sotorasib with either pembrolizumab or atezolizumab. This seems to be a difficult combination and we’ve previously reported on significant liver adverse events in patients that have been previously IO pretreated, who then received sotorasib. However, investigators with Amgen were able to identify that the combination does have liver toxicities but dose-reducing sotorasib reduces the extent of the liver toxicities and a combination of dose reduction together with run-in monotherapy with sotorasib after combination therapy, can mitigate against some of the problems identified with ALT rises. And so we look forward to seeing how this combination is then further developed and more data coming through on this particular combination.
Read more...
